Avalo Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 121.29 million compared to USD 9.96 million a year ago. Basic loss per share from continuing operations was USD 141 compared to USD 204 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.49 USD | +4.31% | +4.36% | +26.26% |
May. 13 | Avalo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 17 | North American Morning Briefing : Stock Futures -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.26% | 11.39M | |
+48.54% | 56.87B | |
+37.15% | 39.72B | |
-6.02% | 39.27B | |
-6.90% | 28.73B | |
+12.97% | 26.21B | |
-16.91% | 19.79B | |
+31.71% | 12.28B | |
+28.18% | 12.23B | |
+0.38% | 12.12B |
- Stock Market
- Equities
- AVTX Stock
- News Avalo Therapeutics, Inc.
- Avalo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024